Figure 5From: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platformsValidation of potential prognostic markers by Taqman® assay-based real-time PCR. 85 marker genes including the minimal set of 54 genes identified to best distinguish the luminal A and the basal-like subtypes were validated by TaqMan® Gene Expression assays. Profile correlation analysis showed the expression profile across the 20 tumor samples determined by the three microarray platforms and by TaqMan® Gene Expression assays are highly correlated with median correlation coefficient R > 0.9 and a rate of good correlation (R > 0.8) of 81–88%.Back to article page